Key facts
- Notable investors include Murex Partners, Magnify.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Meteor Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Meteor Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Meteor Biotech
Developer of spatial cell sorting technology designed to advance tissue analysis and cellular research. The company offers a platform featuring cell sorting, spatial mapping of cells within tissues, and detailed cellular dynamics analysis, enabling research institutions and biotechnology companies to conduct precise, large-scale studies of tissue samples and cellular interactions for improved research outcomes.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2022
- Employees
- 21
- Website
- meteorbiotech.com/
- Ownership
- Privately Held (backing)
Meteor Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Meteor Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Meteor Biotech in its N-PORT filings yet. We sweep new filings monthly.